| Implementing TMB measurement in clinical practice: considerations on assay requirements |
47 |
| Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management |
43 |
| Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors |
32 |
| Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer |
24 |
| Global cancer control: responding to the growing burden, rising costs and inequalities in access |
24 |
| How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies |
23 |
| How we treat patients with lung cancer during the SARS-CoV-2 pandemic:primum non nocere |
22 |
| Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management |
22 |
| New emerging targets in cancer immunotherapy: the role of TIM3 |
21 |
| How we treat glioblastoma |
21 |
| Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion |
20 |
| Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy? |
17 |
| Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature |
16 |
| New emerging targets in cancer immunotherapy: the role of LAG3 |
15 |
| Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey |
14 |
| Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer |
12 |
| Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the observational AQUARiUS study |
12 |
| Interprofessional spiritual care in oncology: a literature review |
12 |
| New emerging targets in cancer immunotherapy: the role of Cluster of Differentiation 40 (CD40/TNFR5) |
11 |
| How we treat patients with leptomeningeal metastases |
11 |
| TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma |
10 |
| Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology |
10 |
| How I treat metastatic triple-negative breast cancer |
10 |
| How I treat ALK-positive non-small cell lung cancer |
10 |
| Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors |
10 |
| Targeted therapy in cervical cancer |
10 |
| Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability |
10 |
| Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer |
10 |
| Immune checkpoint inhibitor treatment in patients with oncogene-addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary roundtable discussion |
10 |
| Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours |
10 |
| UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO) |
9 |
| Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case |
9 |
| Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer |
9 |
| Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity |
9 |
| Predictive value of improvement in the immune tumour microenvironment in patients with breast cancer treated with neoadjuvant chemotherapy |
8 |
| Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer |
8 |
| Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events |
8 |
| ALK IHC and FISH discordant results in patients with NSCLC and treatment response: for discussion of the question-to treat or not to treat? |
8 |
| Report on the status of women occupying leadership roles in oncology |
8 |
| CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary roundtable discussion |
8 |
| Relevance of a molecular tumour board (MTB) for patients' enrolment in clinical trials: experience of the Institut Curie |
8 |
| Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: a case report and a review of literature |
7 |
| Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations |
7 |
| Assessing molecular subtypes of gastric cancer: microsatellite unstable and Epstein-Barr virus subtypes. Methods for detection and clinical and pathological implications |
7 |
| TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer |
7 |
| Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2 |
7 |
| Value of surgical resection and timing of therapy in patients with pancreatic cancer at high risk for positive margins |
7 |
| Prospective analysis of 895 patients on a UK Genomics Review Board |
7 |
| The role of hormone therapy and chemotherapy in oligometastatic prostate cancer |
7 |
| PHOTOSTENT-02: porfimer sodium photodynamic therapy plus stenting versus stenting alone in patients with locally advanced or metastatic biliary tract cancer |
6 |
